Table 5.
Positivity rate of PSMA-11 PET/CT in large published series (n > 200) of patients from different centres with biochemical recurrence (BCR) of prostate cancer, according to serum PSA level assayed for PSMA-11 PET/CT
| Present study | Eiber et al. 2015 [2] | Afshar-Oromieh et al. 2017 [4] | Caroli et al. 2018 [13] | Ceci et al. 2019 [7] | Fendler et al. 2019 [8] | McCarthy et al. 2019 [9] | |
|---|---|---|---|---|---|---|---|
| Origin | 6 centres, France | Munich, Germany | Heidelberg, Germany | Meldola, Italy | Bologna, Italy | San Francisco and Los Angeles, USA | Perth, Australia |
| Number of PSMA-11 PET/CTs | 1084 | 248 | 1007 | 314 | 332 | 635 | 238 |
| Proportion of patients who underwent prostatectomy | 80% | 100% | 82% | 84% | 98% | 73% | 64% |
| Main inclusion criterion (as complement to BCR) | Negative (85%) or equivocal FCH PET/CT. Delay < 100 days | Prostatectomy, no chemotherapy | Initial PET/CT of each patient at BCR | Negative (28%) or dubious FCH PET/CT | PSA between 0.2 and 2.0 ng/mL | No investigational therapy. PET/CT n = 443, PET/MRI n = 192 | 3 or fewer metastases on contrast abdominopelvic CT and bone scintigraphy |
| PSA median (range), ng/mL | 1.7 (0.03–112) | 1.99 (0.2–59.4) | 2.2 (0.01–1237) | 0.83 (0.003–80) | 0.61 (0.2–2) | 2.1 (0.1–1154) | 2.55 |
| Positivity rate | |||||||
|
Overall Pelvic confined/distant |
68% (n = 1084) 34%/36% |
90% (n = 248) | 80% (n = 1007) |
63% (n = 314) 37%/26%* |
54% (n = 332) 25%/29% |
75% (n = 635) 35%/40% |
77% (n = 238) |
|
PSA < 0.2 ng/mL Pelvic confined/distant |
41% (n = 17) 41% / 0% |
- | 46% (n = 69) | 27% (n = 33) | - | 0% (n = 2**) | - |
|
≥ 0.2 PSA < 0.5 ng/mL Pelvic confined/distant |
42% (n = 166) 28%/15% |
58% (n = 19) | 46% (n = 108) | 42% (n = 78) |
38% (n = 138) 17%/21% |
38% (n = 136) | 51% (n = 63) |
|
≥ 0.5 PSA < 1 ng/mL Pelvic confined/distant |
64% (n = 173) 33%/31% |
73% (n = 33) | 73% (n = 119) | 54% (n = 58) |
54% (n = 92) 24% / 29% |
57% (n = 79) | 67% (n = 24) |
|
≥ 1 PSA < 2 ng/mL Pelvic confined/distant |
67% (n = 257) 35%/32% |
93% (n = 72) | 80% (n = 166) | 75% (n = 68) |
71% (n = 102) 27%/43% |
84% (n = 89) | 63% (n = 24) |
|
PSA ≥2 ng/mL Pelvic confined/distant |
81% (n = 471) 38%/51% |
97% (n = 124) | 92% (n = 509)* | 95% (n = 77) | - | 92% (n = 331)* | 94% (n = 127) |
FCH 18F-fluorocholine, n number of PET/CTs, PSA serum level of prostate-specific antigen
*Calculated from data in the article
**Excluded from the analysis by the authors